Table 2.
Concentration of CXCLs in peripheral and tumor draining blood samples (pg/mL) ± SD
| CXCLs | Before treatment (n=69) | After treatment (n=69) | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Peripheral | Tumor draining blood | No recurrence (n=38) | Relapse (n=31) | |||
|
|
|
|||||
| Peripheral | Tumor draining blood | Peripheral | Tumor draining blood | |||
| CXCL1 | 156.23±47.36 | 137.46±32.57 | 36.78±9.87* | 26.22±11.45* | 239.13±103.27# | 198.47±34.21# |
| CXCL2 | 246.89±35.12 | 309.82±49.44 | 50.17±12.89* | 66.17±25.13* | 451.213±89.24# | 486.53±157.16# |
| CXCL3 | 486.79±108.55 | 389.21±67.15 | 419.21±75.11 | 513.16±65.24 | 637.99±79.46 | 789.31±109.44 |
| CXCL4 | 2672.28±389.77 | 2107.26±416.34 | 2145.35±479.39 | 1954.17±581.1 | 3657.71±897.33# | 4016.64±1023.38# |
| CXCL5 | 568.79±108.11 | 541.26±200.37 | 357.65±79.15* | 311.37±127.68* | 986.32±177.64# | 1089.21±208.42# |
| CXCL6 | 301.35±63.17 | 289.47±78.21 | 219.68±111.29 | 256.17±101.35 | 416.37±109.57 | 468.18±148.39 |
| CXCL7 | 1255.27±227.34 | 1536.15±242.45 | 1419.88±239.65 | 1549.58±309.17 | 1002.41±218.29# | 889.53±108.57# |
| CXCL8 | 58.24±9.78 | 76.29±7.88 | 21.89±11.13* | 29.15±7.43* | 164.45±17.66# | 186.64±29.69# |
| CXCL9 | 754.14±109.85 | 656.67±98.33 | 538.22±125.75 | 678.26±218.31 | 1176.11±210.45# | 1258.17±117.46# |
| CXCL10 | 86.46±19.89 | 112.29±23.73 | 56.54±11.24 | 64.76±11.68 | 189.43±35.51# | 214.61±45.28# |
| CXCL11 | 35.26±5.79 | 46.28±11.37 | 86.18±27.78* | 96.27±33.18* | 67.56±8.91 | 72.79±11.61 |
| CXCL12 | 26.21±6.76 | 31.27±10.07 | 56.57±27.63 | 76.62±18.97 | 15.11±4.38# | 19.41±8.19# |
| CXCL13 | 489.11±87.43 | 556.17±109.46 | 201.77±49.78* | 196.39±57.66* | 866.15±78.93# | 796.84±174.51# |
| CXCL14 | 87.27±20.31 | 96.64±19.39 | 138.23±27.76 | 186.78±50.33 | 36.16±7.95# | 29.69±9.61# |
Compared with before treatment;
*
P < 0.05.
Compared with no recurrence;
#
P < 0.05.